warning

Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

Title  
JNJ 64007957MMY1001: A phase I, First-in-Human, Open-Label, Dose Escalatin Study of JNJ 64007957, a Humanized BCMA x CD3 DuoBody in Subjects with Relapsed or Refractory Multiple Myeloma
Brief Description  
Primary: 1. Part I- Dose Escalation to identify the recommended Phase 2 dose(s) RP2D and schedule for JNJ-64007957. 2. Part 2- Dose Expansion to characterize the safety and tolerability of JNJ-64007957 at the RP2D (s).
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Multiple Myeloma
Status  
OPEN
Start Date  
05/30/2017
IRB Number  
00021177
Principal Investigator  
Usmani, Saad Zafar
Contact Name  
Tesa M Adams

For More Information, Contact  Tesa  M, Adams
Phone:  980-442-2335 Fax:    
Email:  Tesa.Adams@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, NC 28204
Close